Skip to main content
Towards parmanent cure of intractable diseases
Expectations are rising for regenerative medicine as an innovative therapy to cure diseases that were hitherto difficult to treat with by conventional drugs. In order for regenerative medicine to become widely accessible, it will be necessary to develop manufacturing technologies for the mass production of high quality cells required for medical use at a low cost. At Hitachi, we are developing closed-type cell automated cell culture equipment for regenerative medicine.
The equipment developed by Hitachi is equipped with completely closed culture vessels and fluid circuits to avoid bacterial contamination from outside, etc. An advantage feature of the closed fluid circuit is the high-precision fluid and gas transport mechanisms enabling multiple culture. Further, the culture vessels and fluid circuits were designed as a single-use module to prevent cross-contamination between patients. In collaboration with academia, an automated cell culture system has been developed. Automated culture of human oral mucosal cells verified the quality of regenerated tissues is equal to that of manually cultured tissue. As the next step to apply this technology for various cells such as for human induced pluripotent stem (iPS) cells. We will be pursuing open innovation with academia and pharmaceutical companies.
A part of this research was supported by the following national projects.
- "Creation of Innovation Center for Advanced Interdisciplinary Research Areas Program," Ministry of Education, Culture, Sports, Science and Technology, Japan
- "Funding Program for World-Leading Innovative R&D on Science and Technology" (FIRST Program), Cabinet Office, Japan
- "Project Focused on Developing Key Evaluation Technology: Evaluation for Industrialization in the Field of Regenerative Medicine," Japan Agency for Medical Research and Development